Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 12,734 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Male Clear all
Withdrawn Phase 1Phase 2 Interventional

Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer

NCT03111901
View directory record Official record
Conditions
Carcinoma, Renal Cell, Melanoma
Interventions
Pembrolizumab, Interleukin-2
Drug
Lead sponsor
William Grosh, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 12, 2019 · Synced Oct 22, 2026, 5:59 AM EDT
Completed Phase 1 Interventional

Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors

NCT01661400
View directory record Official record
Conditions
Glioma, Neuroectodermal Tumors, Primitive, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Retinoblastoma
Interventions
Metronomic Cyclophosphamide, Thalidomide
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
6 Months to 21 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 22, 2026, 5:59 AM EDT
Completed Not applicable Interventional

The "Step4Life" Randomized Control Trial in Hemodialysis

NCT05241171
View directory record Official record
Conditions
Physical Activity, End Stage Kidney Disease, Hemodialysis
Interventions
Fitbit
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 22, 2026, 5:59 AM EDT
Completed Phase 2 Interventional Results available

A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma

NCT01297244
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Tivozanib
Drug
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
20
States / cities
Mobile, Alabama • Burbank, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 22, 2026, 5:59 AM EDT
Terminated Phase 2 Interventional

Research Study for Patients With Metastatic Renal Cell Carcinoma

NCT00110344
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Nexavar (Sorafenib, BAY43-9006), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 11, 2013 · Synced Oct 22, 2026, 5:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Imaging Plus Urodynamics to Investigate the Brain's Control of the Bladder

NCT01619995
View directory record Official record
Conditions
Urge Urinary Incontinence
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Oct 22, 2026, 5:59 AM EDT
Active, not recruiting No phase listed Observational

PRISM: Patient Experiences With PET Imaging in Prostate Cancer

NCT06523777
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
7
States / cities
Bridgeport, Connecticut • Derby, Connecticut • Greenwich, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 22, 2026, 5:59 AM EDT
Completed No phase listed Observational

Impact Of Sacral Neuromodulation On Urine Markers For Interstitial Cystitis (IC)

NCT00704457
View directory record Official record
Conditions
Interstitial Cystitis
Interventions
Not listed
Lead sponsor
Kenneth Peters, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 22, 2026, 5:59 AM EDT
Recruiting Not applicable Interventional

Comparison of Urinary Flow Study

NCT06918067
View directory record Official record
Conditions
Urinary Retention
Interventions
Coloplast Micro Zone Luja Female Catheter, Coloplast SpeediCath Female Catheter
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 22, 2026, 5:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence and Food Effect of 250mg of Lamotrigine XR

NCT00605371
View directory record Official record
Conditions
Epilepsy
Interventions
Lamotrigine tablet, Lamotrigine caplet
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years to 55 Years
Enrollment
209 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 22, 2026, 5:59 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Peripheral Blood Flow Responses to Electromagnetic Energy

NCT02370199
View directory record Official record
Conditions
Exposure to Man-made Visible Light
Interventions
670 nm light, octafluropropane
Device · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 59 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 22, 2026, 5:59 AM EDT
Completed Phase 1 Interventional Results available

AGN-Cogni.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients

NCT05375539
View directory record Official record
Conditions
Prostate Cancer
Interventions
AGN-Cogni.Q
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
40 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 22, 2026, 5:59 AM EDT
Completed Phase 1 Interventional Results available

Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy

NCT01221181
View directory record Official record
Conditions
Dense Deposit Disease, Membranoproliferative Glomerulonephritis
Interventions
Eculizumab
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Oct 22, 2026, 5:59 AM EDT
Not listed Phase 1Phase 2 Interventional

Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer

NCT00121095
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Samarium Sm-153 lexidronam + Docetaxel
Drug
Lead sponsor
Cytogen Corporation
Industry
Eligibility
Male only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 21, 2007 · Synced Oct 22, 2026, 5:59 AM EDT
Terminated No phase listed Observational

Duration of Medication Therapy and Outcomes After Holmium Laser Prostate Surgery for Patients With Benign Prostatic Hyperplasia (BPH)

NCT03768765
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Holmium Laser Prostate Surgery
Procedure
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 22, 2026, 5:59 AM EDT
Completed Phase 1Phase 2 Interventional

An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors

NCT00514267
View directory record Official record
Conditions
Prostate Cancer, Tumors
Interventions
YM 155, Docetaxel, Prednisone
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Oct 22, 2026, 5:59 AM EDT
Completed Phase 4 Interventional

A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease

NCT05951192
View directory record Official record
Conditions
Anemia, Renal Insufficiency, Chronic, Renal Anemia
Interventions
Daprodustat
Drug
Lead sponsor
USRC Kidney Research
Network
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lone Tree, Colorado
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 22, 2026, 5:59 AM EDT
Completed Phase 4 Interventional

Dialysis Clinical Outcomes Revisited (DCOR) Trial

NCT00324571
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Sevelamer hydrochloride, Calcium-based phosphate binder
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
72
States / cities
Gadsden, Alabama • Huntsville, Alabama • Tucson, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 22, 2026, 5:59 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer

NCT00684996
View directory record Official record
Conditions
Recurrent Renal Cell Cancer, Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
etaracizumab, bevacizumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Marysville, California • Sacramento, California • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Oct 22, 2026, 5:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring

NCT04037254
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions
Gonadotrophin Releasing Hormone, Intensity-Modulated Radiation Therapy, Niraparib
Biological · Radiation · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
94
States / cities
Gilbert, Arizona • Tucson, Arizona • Duarte, California + 77 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 22, 2026, 5:59 AM EDT
Completed Not applicable Interventional Results available

Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfunction

NCT06059066
View directory record Official record
Conditions
Neurogenic Bladder, Lower Urinary Tract Symptoms, Overactive Bladder, Neuro: Neurogenic Bladder, Neurogenic Detrusor Overactivity
Interventions
Standard number of injection sites, Reduced number of injection sites
Procedure
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 22, 2026, 5:59 AM EDT
Withdrawn Phase 4 Interventional

Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access

NCT04614142
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Hepatitis c
Interventions
Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
34 Years to 44 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 22, 2026, 5:59 AM EDT
Completed Not applicable Interventional Results available

MRI Based Active Selection for Treatment Trial

NCT02242773
View directory record Official record
Conditions
Prostate Cancer
Interventions
Multi-Parametric MRI, MRI-Guided Biopsy
Device
Lead sponsor
University of Miami
Other
Eligibility
35 Years to 85 Years · Male only
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 22, 2026, 5:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Food on Nemtabrutinib (MK-1026) in Healthy Participants (MK-1026-016)

NCT06772805
View directory record Official record
Conditions
Healthy
Interventions
Nemtabrutinib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 22, 2026, 5:59 AM EDT